Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc.A (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2019, at 9:00 a.m. PT.
A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.AboutA Rubius Therapeutics
Rubius TherapeuticsA is a biopharmaceutical company developing a new class of medicines called Red Cell Therapeuticsa??. The Companya??s proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeuticsa?? that are selective, potent and ready-to-use allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubiusa?? initial focus is to advance RCTa?? product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities a?? cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visitA,A or follow us onA Twitter and LinkedIn.Contacts:
Lori MelanA§on
Vice President, Corporate Communications and Investor Relations
+1 (617) 229-6122
lori.melancon@rubiustx.comMedia Contact:A 
Dan Budwick
1AB, Inc.
+1 (973) 271-6085
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2020    »